Gilead Sciences (NASDAQ:GILD) shares surged 4.5% to $172.99 in premarket trading on Friday after the biopharmaceutical company reported third-quarter 2026 earnings and revenue substantially above Wall Street expectations, raised its full-year sales outlook and recorded strong growth across its HIV treatment and prevention business.
The company’s results, released after Thursday’s market close, showed adjusted earnings of $2.55 per share, comfortably exceeding analysts’ consensus estimate of approximately $2.17. Revenue reached $8.3 billion, compared with expectations of around $7.79 billion.
Investor confidence was further strengthened by Gilead’s decision to increase its full-year product sales guidance to between $31.0 billion and $31.3 billion, supported by rising demand for its HIV medicines.
The rally pushed Gilead shares above their previous 52-week high of $165.70, extending gains recorded during the preceding trading session and after-hours trading.
The advance was particularly notable because broader US equity markets were declining, highlighting the strength of the company’s earnings-driven momentum.
Gilead reported adjusted earnings of $2.55 per share for the third quarter of 2026, exceeding Wall Street’s consensus estimate of approximately $2.17.
The result represented an earnings beat of around 17.5%, reflecting stronger profitability than analysts had anticipated.
Quarterly revenue reached $8.3 billion, surpassing expectations of approximately $7.79 billion by more than 6%.
The combination of higher-than-expected earnings and revenue demonstrated the strength of Gilead’s underlying pharmaceutical business.
Chief Executive Daniel O’Day described the performance as the company’s “strongest year-over-year base business growth in more than a decade.”
The comments highlighted the significance of the quarter for Gilead, particularly as its established HIV medicines continued generating substantial revenue.
Investors responded positively to the results because they showed that the company was delivering growth in its core operations rather than relying solely on cost reductions or other non-recurring factors.
The earnings performance also provided a stronger foundation for management’s improved full-year outlook.
Gilead’s HIV treatment and prevention portfolio was the principal contributor to its stronger-than-expected quarterly results.
Total HIV product sales increased 18% year over year to $6.2 billion, supported by strong demand for the company’s medicines.
The increase represented a substantial contribution to Gilead’s overall quarterly revenue of $8.3 billion.
Demand for HIV prevention treatments was an important factor behind the growth, reflecting continued expansion in the company’s prevention business.
The performance demonstrated the importance of Gilead’s HIV franchise to its financial results and longer-term commercial strategy.
HIV medicines remain a central component of the company’s pharmaceutical portfolio, providing a substantial source of revenue and operating cash flow.
The latest quarterly figures indicated that demand remained strong across the business, supporting both revenue growth and improved profitability.
For investors, the 18% increase in HIV sales provided evidence that Gilead’s core business continued expanding at a meaningful pace.
One of the most significant developments in Gilead’s third-quarter report was the performance of BIKTARVY, its leading HIV treatment.
The medicine achieved a record 53% share of the US HIV treatment market.
The milestone demonstrated BIKTARVY’s strong competitive position and its importance within Gilead’s HIV portfolio.
A market share above 50% indicates that the treatment accounts for more than half of the relevant US market, providing Gilead with a substantial presence in HIV care.
The record performance also supported investor confidence in the company’s ability to maintain demand for its established medicines.
Strong market positioning can help pharmaceutical companies sustain revenue by supporting continued prescriptions and treatment adoption.
For Gilead, BIKTARVY’s performance was particularly important because the HIV business generated $6.2 billion in quarterly sales.
The combination of record treatment market share and growing demand for prevention medicines strengthened the company’s overall commercial performance.
However, maintaining this position will depend on continued demand, competitive developments and the company’s ability to support its treatment portfolio.
Following the stronger-than-expected third quarter, Gilead increased its full-year 2026 product sales guidance to between $31.0 billion and $31.3 billion.
The midpoint of the revised range, $31.15 billion, exceeded the previous analyst consensus.
The higher forecast reflected management’s increased confidence in the company’s revenue outlook following strong performance in its HIV business.
Raising annual guidance after reporting better-than-expected quarterly results can signal that management expects favourable business conditions to continue.
For Gilead, the revised outlook was supported by rising HIV product sales and strong demand for its treatment and prevention medicines.
The guidance increase was particularly important because it suggested that the company’s quarterly performance was contributing to stronger expectations for the full financial year.
Investors also viewed the revision as evidence that Gilead’s core pharmaceutical operations were performing ahead of earlier projections.
The improved sales outlook became one of the principal catalysts behind the 4.5% premarket share price increase.
Gilead generated $5.0 billion in operating cash flow during the third quarter.
The substantial cash generation demonstrated the financial strength of its established pharmaceutical business.
Operating cash flow measures the cash generated through a company’s normal business activities and provides an important indication of its ability to fund operations and investments.
For pharmaceutical companies, strong cash generation can support research and development, commercial expansion and other strategic priorities.
Gilead’s quarterly operating cash flow also reinforced the positive message from its earnings and revenue performance.
The figure suggested that the company’s growth was accompanied by substantial cash generation, rather than being reflected only in accounting profits.
This was particularly relevant to investors evaluating the durability of Gilead’s HIV franchise and its capacity to support future business development.
Combined with the raised sales guidance, the cash flow performance contributed to a favourable assessment of the company’s financial position.
Analyst sentiment also provided support for Gilead shares ahead of the earnings announcement.
Jefferies raised its price target on the stock to $185 while maintaining a Buy rating.
The revised target reflected the investment bank’s favourable assessment of Gilead’s prospects before the company released its third-quarter results.
The subsequent earnings beat and higher full-year guidance provided additional support for the positive outlook.
At the reported premarket price of $172.99, Jefferies’ $185 target represented approximately 6.9% potential upside.
However, analyst price targets represent forecasts rather than guarantees of future share price performance.
The combination of a favourable analyst assessment and stronger-than-expected financial results contributed to the positive sentiment surrounding Gilead.
The company’s record HIV treatment market share and substantial operating cash flow provided further reasons for investors to reassess its valuation.
Gilead’s rally occurred against a constructive backdrop for the broader pharmaceutical industry.
Sector peers Merck (NYSE:MRK) and Eli Lilly (NYSE:LLY) both reported strong third-quarter 2026 results on October 29 and increased their full-year guidance.
The positive announcements contributed to improving sentiment towards major pharmaceutical companies.
Strong earnings across several businesses can reinforce investor confidence in the industry’s revenue growth and profitability prospects.
For Gilead, the favourable sector environment provided additional support following its own better-than-expected results.
However, the company’s 4.5% premarket advance was primarily driven by its specific financial performance, higher sales outlook and strong HIV business.
The broader pharmaceutical sector’s positive earnings trend helped distinguish Gilead’s performance from the weakness affecting many technology and growth-oriented stocks.
Investors were therefore responding to both company-specific developments and a more favourable earnings environment across the pharmaceutical industry.
Gilead’s premarket gains contrasted with declines across the broader US stock market.
The Nasdaq fell 2.2%, while the S&P 500 declined 1.0%, reflecting selling pressure across technology and other growth-oriented equities.
Despite this weakness, Gilead shares advanced 4.5%, demonstrating the importance of its earnings announcement in driving investor demand.
Pharmaceutical companies can attract attention during periods of broader market uncertainty when they report strong revenue growth, profitability and cash generation.
Gilead’s third-quarter results provided several positive developments, including higher-than-expected earnings, record HIV market share and improved full-year guidance.
These factors helped the stock outperform major US indexes during premarket trading.
The positive performance also reflected confidence in the company’s established medicines and the strength of its underlying business.
While broader market conditions could still influence trading during the regular session, Gilead’s earnings results remained the dominant catalyst behind the rally.
Gilead shares reached $172.99 in premarket trading, moving above their previous 52-week high of $165.70.
The new level represented an increase of approximately 4.4% above the earlier annual high.
The advance extended positive momentum that had begun during Thursday’s regular trading session and continued after the earnings announcement.
Breaking above a previous 52-week high can attract additional investor attention because it indicates that the stock has reached a new trading level relative to its recent history.
In Gilead’s case, the move was supported by stronger earnings, higher revenue expectations and record market share in its leading HIV treatment.
The rally also demonstrated that investors were willing to increase their exposure to the company despite weakness across the broader equity market.
However, a new annual high does not guarantee further gains, and future performance will depend on Gilead’s ability to maintain its operating momentum.
The company’s raised sales outlook and strong cash generation will remain important factors in determining whether the positive sentiment continues.
Investors will be watching whether Gilead can sustain the strong growth recorded across its HIV treatment and prevention portfolio.
Continued demand for BIKTARVY will be particularly important following the medicine’s achievement of a record 53% share of the US HIV treatment market.
The performance of the broader HIV business will also remain central to the company’s financial outlook after quarterly sales increased 18% to $6.2 billion.
Another important factor will be Gilead’s ability to deliver against its revised full-year product sales guidance of $31.0 billion to $31.3 billion.
Strong operating cash flow could provide additional support for the company’s research, development and commercial activities.
Investors will also monitor analyst revisions and financial results from other major pharmaceutical companies as they assess the industry’s broader growth prospects.
Gilead’s 4.5% premarket rally to $172.99 reflected a combination of stronger-than-expected earnings, an improved annual outlook, record HIV treatment market share and substantial cash generation.
With the shares moving above their previous 52-week high, the company’s next challenge will be maintaining the growth momentum that helped deliver what management described as its strongest annual improvement in the underlying business in more than a decade.
Gilead Sciences stock price
| 1 hour | |
| Oct-29 | |
| Oct-29 | |
| Oct-29 |
Gilead Sciences Lifts Sales Guidance on HIV Portfolio Strength
GILD GILD +5.23%
The Wall Street Journal
|
| Oct-29 | |
| Oct-29 |
How Gilead, Which Just Hit A Record, Notched Its Best Sales Growth In A Decade
GILD GILD +5.23%
Investor's Business Daily
|
| Oct-29 | |
| Oct-29 | |
| Oct-26 | |
| Oct-26 | |
| Oct-23 | |
| Oct-23 | |
| Oct-22 | |
| Oct-21 | |
| Oct-19 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite